LYVE-1 (E9VA4): sc-65647



The Power to Question

BACKGROUND

Lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) is expressed on the cell surface as a protein that is reduced by glycosidase treatment. LYVE-1 is abundant in spleen, lymph node, heart, lung and fetal liver, and is less abundant in appendix, bone marrow, placenta, muscle and adult liver. Expression of LYVE-1 is largely restricted to endothelial cells lining lymphatic vessels and splenic sinusoidal endothelial cells. LYVE-1 binds to both soluble and immobilized hyaluronan (HA) with greater specificity than HCAM. Like HCAM, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike HCAM, the LYVE-1 molecule co-localizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves. LYVE-1 is used as a marker to study tumor lymphangiogenesis, which is an important area of investigation.

REFERENCES

- 1. Banerji, S., et al. 1999. LYVE-1, a new homolog of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 144: 789-801.
- Online Mendelian Inheritance in Man, OMIM™. 2001. Johns Hopkins University, Baltimore, MD. MIM Number: 605702. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/
- Gale, N.W., et al. 2007. Normal lymphatic development and function in mice deficient for the lymphatic hyaluronan receptor LYVE-1. Mol. Cell. Biol. 27: 595-604.

CHROMOSOMAL LOCATION

Genetic locus: Lyve1 (mouse) mapping to 7 F1.

SOURCE

LYVE-1 (E9VA4) is a rat monoclonal antibody raised against the extracellular domain of recombinant LYVE-1 of mouse origin.

PRODUCT

Each vial contains 200 μg lgM in 1.0 mL PBS with <0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

LYVE-1 (E9VA4) is recommended for detection of LYVE-1 of mouse origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)] and immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

Suitable for use as control antibody for LYVE-1 siRNA (m): sc-42902, LYVE-1 shRNA Plasmid (m): sc-42902-SH and LYVE-1 shRNA (m) Lentiviral Particles: sc-42902-V.

Molecular Weight of LYVE-1: 40 kDa.


Molecular Weight of glycosylated LYVE-1: 60 kDa.

Positive Controls: mouse lung extract: sc-2390 or mouse lymph node extract: sc-364243.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

DATA



LYVE-1 (E9VA4): sc-65647. Western blot analysis of LYVE-1 expression in mouse lung tissue extract.

SELECT PRODUCT CITATIONS

- Kelley, P.M., et al. 2011. Regressed lymphatic vessels develop during corneal repair. Lab. Invest. 91: 1643-1651.
- Fink, D.M., et al. 2014. Nerve growth factor regulates neurolymphatic remodeling during corneal inflammation and resolution. PLoS ONE 9: e112737.
- Chen, H. and Dai, J. 2018. MiR-409-3p suppresses the proliferation, invasion and migration of tongue squamous cell carcinoma via targeting RDX. Oncol. Lett. 16: 543-551.
- Cano-Ballesteros, S., et al. 2021. Fsp1 cardiac embryonic expression delineates atrioventricular endocardial cushion, coronary venous and lymphatic valve development. J. Anat. 238: 508-514.
- Nishida-Fukuda, H., et al. 2021. Evaluation of the antiproliferative effects of the HASPIN inhibitor CHR-6494 in breast cancer cell lines. PLoS ONE 16: e0249912.
- Paulson, D., et al. 2021. Loss of primary cilia protein IFT20 dysregulates lymphatic vessel patterning in development and inflammation. Front. Cell Dev. Biol. 9: 672625.
- Zhou, J., et al. 2021. ADSCs enhance VEGFR3-mediated lymphangiogenesis via METTL3-mediated VEGF-C m6A modification to improve wound healing of diabetic foot ulcers. Mol. Med. 27: 146.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com